These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36781332)

  • 61. Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study.
    Mar J; Ibarrondo O; Estadilla CDS; Stollenwerk N; Antoñanzas F; Blasco-Aguado R; Larrañaga I; Bidaurrazaga J; Aguiar M
    Pharmacoeconomics; 2024 Feb; 42(2):219-229. PubMed ID: 37910377
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: a modelling and economic analysis study.
    Drakesmith M; Collins B; Jones A; Nnoaham K; Thomas DR
    BMC Health Serv Res; 2022 Sep; 22(1):1190. PubMed ID: 36138455
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessing the impact of Australia's mass vaccination campaigns over the Delta and Omicron outbreaks.
    Lin L; Demirhan H; P Johnstone-Robertson S; Lal R; M Trauer J; Stone L
    PLoS One; 2024; 19(4):e0299844. PubMed ID: 38626045
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-effectiveness of COVID-19 vaccination: A systematic review.
    Fu Y; Zhao J; Han P; Zhang J; Wang Q; Wang Q; Wei X; Yang L; Ren T; Zhan S; Li L
    J Evid Based Med; 2023 Jun; 16(2):152-165. PubMed ID: 37186130
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cost-based COVID-19 vaccination and willingness to pay: A post-pandemic review.
    Wong LP; Lee HY; Alias H; Zimet G; Liu T; Lin Y; Hu Z
    Hum Vaccin Immunother; 2024 Dec; 20(1):2313860. PubMed ID: 38359815
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Everyone Wins: Vaccine Lotteries Can Cost-Effectively Increase COVID-19 Booster Vaccination Rates.
    McLaren ZM
    Am J Epidemiol; 2023 Apr; 192(4):510-513. PubMed ID: 36642497
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Modelling COVID-19 Vaccination in the UK: Impact of the Autumn 2022 and Spring 2023 Booster Campaigns.
    Mendes D; Machira Krishnan S; O'Brien E; Padgett T; Harrison C; Strain WD; Manca A; Ustianowski A; Butfield R; Hamson E; Reynard C; Yang J
    Infect Dis Ther; 2024 May; 13(5):1127-1146. PubMed ID: 38662331
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Economic evaluation of COVID-19 rapid antigen screening programs in the workplace.
    Vilches TN; Rafferty E; Wells CR; Galvani AP; Moghadas SM
    BMC Med; 2022 Nov; 20(1):452. PubMed ID: 36424587
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Australia's Response to COVID-19.
    Stobart A; Duckett S
    Health Econ Policy Law; 2022 Jan; 17(1):95-106. PubMed ID: 34311803
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Cost-Benefit Analysis of COVID-19 Vaccination in Catalonia.
    López F; Català M; Prats C; Estrada O; Oliva I; Prat N; Isnard M; Vallès R; Vilar M; Clotet B; Argimon JM; Aran A; Ara J
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062719
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Intradermal versus intramuscular COVID-19 vaccination aiming at protection for delta variant: cost utility analysis.
    Mungmunpuntipantip R; Wiwanitkit V
    Indian J Pharmacol; 2022; 54(6):462-463. PubMed ID: 36722559
    [No Abstract]   [Full Text] [Related]  

  • 72. Reminders, but not monetary incentives, increase COVID-19 booster uptake.
    Chang TY; Jacobson M; Shah M; Kopetsky M; Pramanik R; Shah SB
    Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2302725120. PubMed ID: 37487101
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A general framework for optimising cost-effectiveness of pandemic response under partial intervention measures.
    Nguyen QD; Prokopenko M
    Sci Rep; 2022 Nov; 12(1):19482. PubMed ID: 36376551
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-effectiveness analysis of COVID-19 screening strategy under China's dynamic zero-case policy.
    Li H; Zhang H
    Front Public Health; 2023; 11():1099116. PubMed ID: 37228729
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Alopecia areata induced by the booster shot of Sinovac COVID-19 vaccination: a case report.
    Wu Y; Dai Y; Peng J; Song X
    Eur J Dermatol; 2022 Nov; 32(6):804-805. PubMed ID: 36856386
    [No Abstract]   [Full Text] [Related]  

  • 76. Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals.
    Su B; Vanham G
    AIDS; 2023 Apr; 37(5):837-839. PubMed ID: 36919787
    [No Abstract]   [Full Text] [Related]  

  • 77. The epidemiological relevance of the COVID-19-vaccinated population is decreasing after booster vaccination, as shown by incidence rate ratios-author's reply.
    Kampf G
    Lancet Reg Health Eur; 2022 May; 16():100376. PubMed ID: 35392451
    [No Abstract]   [Full Text] [Related]  

  • 78. Number needed to vaccinate for COVID-19 booster doses: a valuable metric to inform vaccination strategies.
    Feng S; Lin E; Cowling BJ
    Lancet Reg Health Am; 2023 Jul; 23():100548. PubMed ID: 37397875
    [No Abstract]   [Full Text] [Related]  

  • 79. Incremental benefit of booster vaccinations for COVID-19 in the United Kingdom.
    Cowling BJ; Sullivan SG
    Lancet Reg Health Eur; 2023 Dec; 35():100790. PubMed ID: 38115958
    [No Abstract]   [Full Text] [Related]  

  • 80. Cost-effectiveness of artificial intelligence-assisted liquid-based cytology testing for cervical cancer screening in China.
    Shen M; Zou Z; Bao H; Fairley CK; Canfell K; Ong JJ; Hocking J; Chow EPF; Zhuang G; Wang L; Zhang L
    Lancet Reg Health West Pac; 2023 May; 34():100726. PubMed ID: 37283979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.